Kura Oncology to Participate in Three Upcoming Investor Conferences
May 26, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports First Quarter 2022 Financial Results
May 04, 2022 16:05 ET
|
Kura Oncology, Inc.
– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – – Enrollment in PIK3CA-dependent cohort in...
Kura Oncology to Report First Quarter 2022 Financial Results
April 27, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
April 08, 2022 13:00 ET
|
Kura Oncology, Inc.
– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor – –...
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
March 08, 2022 17:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Two Upcoming Investor Conferences
February 28, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022 16:03 ET
|
Kura Oncology, Inc.
– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data readouts from KOMET-001 expected in 2022 – – First patients dosed in Phase...
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
February 17, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
February 10, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Expands Leadership Team with Key Promotions
February 01, 2022 16:01 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...